Product Name
SPTA1, siRNA
Full Product Name
SPTA1 siRNA (Mouse)
Product Synonym Names
SPNA1; SPTA; Spectrin alpha chain. erythrocytic 1; Erythroid alpha-spectrin
Product Gene Name
SPTA1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P08032
Specificity
SPTA1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse SPTA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SPTA1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SPTA1 sirna
siRNA to inhibit SPTA1 expression using RNA interference
Applications Tested/Suitable for SPTA1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SPTA1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_035595.2
[Other Products]
NCBI GenBank Nucleotide #
NM_011465.4
[Other Products]
UniProt Primary Accession #
P08032
[Other Products]
UniProt Secondary Accession #
P97502; B2RWX6[Other Products]
UniProt Related Accession #
P08032[Other Products]
Molecular Weight
279,865 Da
NCBI Official Full Name
spectrin alpha chain, erythrocytic 1
NCBI Official Synonym Full Names
spectrin alpha, erythrocytic 1
NCBI Official Symbol
Spta1??[Similar Products]
NCBI Official Synonym Symbols
ha; ihj; sph; nmf4; Spna1; Spna-1; AF093576; AI451697
??[Similar Products]
NCBI Protein Information
spectrin alpha chain, erythrocytic 1
UniProt Protein Name
Spectrin alpha chain, erythrocytic 1
UniProt Synonym Protein Names
Erythroid alpha-spectrin
UniProt Gene Name
Spta1??[Similar Products]
UniProt Synonym Gene Names
Spna1; Spta??[Similar Products]
UniProt Entry Name
SPTA1_MOUSE
UniProt Comments for SPTA1
SPTA1: Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane. Defects in SPTA1 are the cause of elliptocytosis type 2 (EL2). EL2 is a Rhesus-unlinked form of hereditary elliptocytosis, a genetically heterogeneous, autosomal dominant hematologic disorder. It is characterized by variable hemolytic anemia and elliptical or oval red cell shape. Defects in SPTA1 are a cause of hereditary pyropoikilocytosis (HPP). HPP is an autosomal recessive disorder characterized by hemolytic anemia, microspherocytosis, poikilocytosis, and an unusual thermal sensitivity of red cells. Defects in SPTA1 are the cause of spherocytosis type 3 (SPH3); also known as hereditary spherocytosis type 3 (HS3). Spherocytosis is a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. SPH3 is characterized by severe hemolytic anemia. Inheritance is autosomal recessive. Belongs to the spectrin family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Cytoskeletal; Motility/polarity/chemotaxis
Cellular Component: cortical cytoskeleton; spectrin; cytoskeleton; membrane; cytoplasm
Molecular Function: protein heterodimerization activity; metal ion binding; calcium ion binding; actin binding
Biological Process: regulation of cell shape; positive regulation of protein binding; plasma membrane organization and biogenesis; actin filament capping; hemopoiesis; positive regulation of T cell proliferation; actin cytoskeleton organization and biogenesis; lymphocyte homeostasis; porphyrin biosynthetic process
Research Articles on SPTA1
1. Calcium plays a role in regulating the expression and function of beta-adducin to sustain normal organization of the spectrin-based cytoskeleton and the differentiation properties in keratinocytes through the calmodulin/EGFR/cadherin signaling pathway.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
